Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook
Authors
Keywords
-
Journal
Journal of Hepatocellular Carcinoma
Volume Volume 9, Issue -, Pages 233-263
Publisher
Informa UK Limited
Online
2022-03-30
DOI
10.2147/jhc.s358082
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
- (2022) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2021) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.
- (2021) Anthony B. El-Khoueiry et al. JOURNAL OF CLINICAL ONCOLOGY
- Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC).
- (2021) Mark Yarchoan et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells
- (2021) Simon J Dovedi et al. Cancer Discovery
- Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma
- (2021) Neehar D Parikh et al. Journal of Comparative Effectiveness Research
- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
- (2021) Philippe Rochigneux et al. Cancers
- Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
- (2021) Ilario Giovanni Rapposelli et al. Cancers
- Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
- (2021) Chi-leung Chiang et al. JAMA Network Open
- Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
- (2021) A. Vogel et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy
- (2021) Alessandro Rizzo et al. Future Oncology
- Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
- (2021) Jeffrey Sum Lung Wong et al. Journal for ImmunoTherapy of Cancer
- Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α ‐fetoprotein: Outcomes by treatment‐emergent ascites
- (2021) Masatoshi Kudo et al. HEPATOLOGY RESEARCH
- Advances in immunotherapy for hepatocellular carcinoma
- (2021) Bruno Sangro et al. Nature Reviews Gastroenterology & Hepatology
- FDA Approval Summary: Nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib
- (2021) May Tun Saung et al. ONCOLOGIST
- Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
- (2021) Xin Zhang et al. JAMA Network Open
- Recent advances in immunotherapy for hepatocellular carcinoma
- (2021) Abid Ali Khan et al. Hepatobiliary & Pancreatic Diseases International
- Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.
- (2021) Li Bai et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
- (2021) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
- (2021) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
- (2021) Masatoshi Kudo et al. JOURNAL OF HEPATOLOGY
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
- (2021) Zhenggang Ren et al. LANCET ONCOLOGY
- Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor
- (2021) Tomoharu Yamada et al. LIVER INTERNATIONAL
- Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives
- (2021) Yung-Yeh Su et al. SEMINARS IN LIVER DISEASE
- YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment
- (2021) Xiaochen Yang et al. Scientific Reports
- Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma
- (2021) Arndt Vogel et al. Liver Cancer
- Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
- (2021) Yuan-Hung Kuo et al. Frontiers in Oncology
- Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
- (2021) Arndt Vogel et al. Lancet Gastroenterology & Hepatology
- Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
- (2021) Yulei Wang et al. Experimental Hematology & Oncology
- Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: A focus on epithelial-mesenchymal transition
- (2021) Jia-jia Li et al. Journal of Integrative Medicine-JIM
- Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
- (2021) David J. Pinato et al. EUROPEAN JOURNAL OF CANCER
- Systemic treatment of hepatocellular carcinoma: An EASL position paper
- (2021) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma
- (2021) Ruwanthi Kolamunnage-Dona et al. JOURNAL OF HEPATOLOGY
- Immunotherapies for hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma
- (2021) Yang Yang et al. Frontiers in Oncology
- CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma
- (2020) Yurong Gu et al. Aging-US
- A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
- (2020) Xiaoyu Li et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Ramucirumab: A Review in Hepatocellular Carcinoma
- (2020) Yahiya Y. Syed DRUGS
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2020) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.
- (2020) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of locoregional therapies in the wake of systemic therapy
- (2020) Daniel H. Palmer et al. JOURNAL OF HEPATOLOGY
- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
- (2020) Robin K. Kelley et al. ADVANCES IN THERAPY
- Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials
- (2020) Donghua Shi et al. CLINICAL CANCER RESEARCH
- Epidemiology of Hepatocellular Carcinoma
- (2020) Katherine A. McGlynn et al. HEPATOLOGY
- Erzhu Qinggan Jiedu Recipe improves the clinical outcome of hepatocellular Cancer after surgical resection: a case-control retrospective study
- (2020) Yang Cheng et al. INTERNAL MEDICINE JOURNAL
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
- (2020) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study
- (2020) Hyung‐Don Kim et al. LIVER INTERNATIONAL
- Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?
- (2020) Yong Xie et al. TUMORI
- Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study
- (2020) Anthony Turpin et al. Clinics and Research in Hepatology and Gastroenterology
- Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study
- (2020) Won-Mook Choi et al. Cancers
- Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
- (2020) Cheol-Hyung Lee et al. Clinical and Molecular Hepatology
- Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma
- (2020) Furong Liu et al. Experimental Hematology & Oncology
- Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
- (2020) Shu‐Kui Qin et al. CANCER SCIENCE
- Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non-randomized, open-label, phase 2 trial
- (2020) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
- (2020) Petros Fessas et al. Journal for ImmunoTherapy of Cancer
- Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240
- (2020) Baek‐Yeol Ryoo et al. CANCER
- Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
- (2020) Eleonora Lai et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Systemic therapy of advanced hepatocellular carcinoma
- (2020) Peter R Galle et al. Future Oncology
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
- (2020) John D. Gordan et al. JOURNAL OF CLINICAL ONCOLOGY
- Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-κB pathway and regulating transporter mediated drug efflux
- (2020) Chen Chen et al. JOURNAL OF ETHNOPHARMACOLOGY
- A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma
- (2020) Chun A. Changou et al. ONCOLOGIST
- Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice
- (2020) Jordi Rimola et al. EUROPEAN JOURNAL OF RADIOLOGY
- Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion
- (2020) Pablo Munoz-Schuffenegger et al. RADIOTHERAPY AND ONCOLOGY
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Child–Pugh Classification: Time to Abandon?
- (2019) Beverley Kok et al. SEMINARS IN LIVER DISEASE
- Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?
- (2019) Yun Huang et al. OncoTargets and Therapy
- Adoptive cell transfer therapy for hepatocellular carcinoma
- (2019) Renyu Zhang et al. Frontiers of Medicine
- Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy
- (2019) Chunfeng Qu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
- (2019) Shuang Qin et al. Journal of Hematology & Oncology
- Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
- (2019) Thomas Cheung Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
- (2019) Max W. Sung et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
- (2019) Ahmed Omar Kaseb et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy
- (2019) Anthony Tanoto Tan et al. GASTROENTEROLOGY
- Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
- (2019) Michael Teufel et al. GASTROENTEROLOGY
- First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
- (2019) Ying Fan et al. BMC CANCER
- Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
- (2019) Eric Assenat et al. BRITISH JOURNAL OF CANCER
- RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
- (2019) Shukui Qin et al. Future Oncology
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.
- (2019) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
- (2019) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune cell therapy for hepatocellular carcinoma
- (2019) Eishiro Mizukoshi et al. Journal of Hematology & Oncology
- Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib ( LY 2157299) in Advanced Hepatocellular Carcinoma
- (2019) Sandrine Faivre et al. LIVER INTERNATIONAL
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
- (2019) MinKe He et al. JAMA Oncology
- O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
- (2019) R Miksad et al. ANNALS OF ONCOLOGY
- LHX3 is an advanced-stage prognostic biomarker and metastatic oncogene in hepatocellular carcinoma
- (2019) Zhong-Lan You Cancer Biomarkers
- Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
- (2019) Enrique Soto-Perez-de-Celis et al. Journal of the National Comprehensive Cancer Network
- Insights into the success and failure of systemic therapy for hepatocellular carcinoma
- (2019) Jordi Bruix et al. Nature Reviews Gastroenterology & Hepatology
- Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells
- (2019) Florian P. Reiter et al. CELLULAR ONCOLOGY
- Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
- (2019) M. Moehler et al. OncoImmunology
- Hepatotoxicity of immune check point inhibitors: Approach and management
- (2019) Ana Lleo et al. DIGESTIVE AND LIVER DISEASE
- Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies
- (2019) Alqahtani et al. Medicina-Lithuania
- A global view of hepatocellular carcinoma: trends, risk, prevention and management
- (2019) Ju Dong Yang et al. Nature Reviews Gastroenterology & Hepatology
- Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report
- (2019) Xin Chen et al. OncoTargets and Therapy
- Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma
- (2019) Ghassan K. Abou-Alfa et al. JAMA Oncology
- 755PAlpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial
- (2019) J Bruix et al. ANNALS OF ONCOLOGY
- 678PDOutcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
- (2019) L Rimassa et al. ANNALS OF ONCOLOGY
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
- (2019) Masaaki Kondo et al. BMC CANCER
- Lenvatinib Versus Sorafenib as First‐Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis
- (2019) John J. Kim et al. ONCOLOGIST
- Immunotherapy for hepatocellular carcinoma
- (2019) Yin Zongyi et al. CANCER LETTERS
- Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma
- (2019) Arndt Vogel et al. CANCER TREATMENT REVIEWS
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA-001Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
- (2018) A Zhu et al. ANNALS OF ONCOLOGY
- Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study
- (2018) Xiao-feng Zhai et al. CANCER
- Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis
- (2018) Hong Zhu et al. CANCER RESEARCH
- Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
- (2018) Alicia J. Angelbello et al. CHEMICAL REVIEWS
- Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients withRAS-mutated Hepatocellular Carcinoma
- (2018) Ho Yeong Lim et al. CLINICAL CANCER RESEARCH
- Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial
- (2018) Qian Chen et al. GUT
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study
- (2018) Yoshiyuki Wada et al. INTERNAL MEDICINE
- Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
- (2018) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
- (2018) Lorenza Rimassa et al. LANCET ONCOLOGY
- Advances in studies of tyrosine kinase inhibitors and their acquired resistance
- (2018) Qinlian Jiao et al. Molecular Cancer
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
- (2018) Changhoon Yoo et al. Cancer Research and Treatment
- Combination Cancer Immunotherapy in Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
- (2018) Chia-Jui Yen et al. Liver Cancer
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up
- (2018) Jeong-Hoon Lee et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
- (2018) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Characteristics of Early Recurrence After Curative Liver Resection for Solitary Hepatocellular Carcinoma
- (2018) Sung-Mi Jung et al. JOURNAL OF GASTROINTESTINAL SURGERY
- The hepatocellular carcinoma market
- (2018) Joshua Dawkins et al. NATURE REVIEWS DRUG DISCOVERY
- Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Epidemiology and Management of Hepatocellular Carcinoma
- (2018) Laura Kulik et al. GASTROENTEROLOGY
- Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma
- (2018) Michael J Flynn et al. HEPATOLOGY
- Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy
- (2018) Aldona Kasprzak et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
- (2018) Joong-Won Park et al. JOURNAL OF HEPATOLOGY
- Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma
- (2018) H. Degroote et al. Journal of Immunology Research
- Oncolytic virus immunotherapy: future prospects for oncology
- (2018) Junaid Raja et al. Journal for ImmunoTherapy of Cancer
- Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein−Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma
- (2017) Hidetoshi Nakagawa et al. GASTROENTEROLOGY
- Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma
- (2017) Rong-Ce Zhao et al. Hepatobiliary & Pancreatic Diseases International
- Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation
- (2017) Franco Trevisani et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies
- (2017) Anthony F. Daniyan et al. Nature Reviews Clinical Oncology
- Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data
- (2017) Sheng-Long Ye et al. TUMOR BIOLOGY
- Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review
- (2017) Bao-Hong Yuan et al. Oncotarget
- Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma
- (2017) Jennifer Eatrides et al. Cancer Control
- T-cell receptor-engineered T cells for cancer treatment: current status and future directions
- (2017) Yu Ping et al. Protein & Cell
- Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study
- (2017) Jeong-Hoon Lee et al. OncoImmunology
- Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
- (2017) Abhishek D. Garg et al. OncoImmunology
- Lenvatinib in Advanced Hepatocellular Carcinoma
- (2017) Masatoshi Kudo Liver Cancer
- A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
- (2017) Masatoshi Kudo Liver Cancer
- Combination immunotherapy: a road map
- (2017) Patrick A. Ott et al. Journal for ImmunoTherapy of Cancer
- Does the underlying etiology of HCC effect outcome? A single-institution analysis.
- (2017) J. Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Selection of Patients with Hepatocellular Carcinoma for Sorafenib
- (2017) Ghassan K. Abou-Alfa Journal of the National Comprehensive Cancer Network
- The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation
- (2017) Matteo Ravaioli et al. Scientific Reports
- A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
- (2016) W. M. Tai et al. ANNALS OF ONCOLOGY
- Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
- (2016) D. Koeberle et al. ANNALS OF ONCOLOGY
- Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
- (2016) Julien Bollard et al. GUT
- Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
- (2016) Ann-Lii Cheng et al. HEPATOLOGY
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC.
- (2016) Mohamed Bouattour et al. JOURNAL OF CLINICAL ONCOLOGY
- Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study
- (2016) Michael Bitzer et al. JOURNAL OF HEPATOLOGY
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma
- (2016) A. R. Singh et al. MOLECULAR CANCER THERAPEUTICS
- Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
- (2016) Omar Abdel-Rahman et al. Expert Review of Gastroenterology & Hepatology
- Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
- (2016) Yu Sawada et al. OncoImmunology
- Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges
- (2016) Li-Chun Lu et al. Liver Cancer
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma
- (2015) Eishiro Mizukoshi et al. CANCER LETTERS
- Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
- (2015) Joon Hyeok Lee et al. GASTROENTEROLOGY
- T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice
- (2015) Christina Dargel et al. GASTROENTEROLOGY
- Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma
- (2015) ZhengGang Ren et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient
- (2015) Waseem Qasim et al. JOURNAL OF HEPATOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma
- (2015) Longhao Sun et al. TUMOR BIOLOGY
- Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate
- (2015) Yaron Meirow et al. Frontiers in Immunology
- A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma
- (2015) Li Xu et al. OncoImmunology
- Targeting RTK Signaling Pathways in Cancer
- (2015) Tarik Regad Cancers
- PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
- (2015) Wing Lam et al. Scientific Reports
- TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications
- (2014) Silvana C. Faria et al. ABDOMINAL IMAGING
- Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
- (2014) Q. Xiang et al. CLINICAL CANCER RESEARCH
- Oxaliplatin-based Chemotherapy: A New Option in Advanced Hepatocellular Carcinoma. A Systematic Review and Pooled Analysis
- (2014) F. Petrelli et al. CLINICAL ONCOLOGY
- Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies
- (2014) Anna Patrikidou et al. INVESTIGATIONAL NEW DRUGS
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study
- (2014) S. Qin et al. ONCOLOGIST
- Staging systems of hepatocellular carcinoma: A review of literature
- (2014) Marcello Maida WORLD JOURNAL OF GASTROENTEROLOGY
- Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
- (2014) Koichi Shimizu et al. Human Vaccines & Immunotherapeutics
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
- (2013) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma
- (2013) Yangyang Hu et al. JOURNAL OF ETHNOPHARMACOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Cytokine-induced killer cells promote antitumor immunity
- (2013) Jingting Jiang et al. Journal of Translational Medicine
- Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
- (2013) G. Brandi et al. ONCOLOGIST
- The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis
- (2012) Joanne Chiu et al. CANCER
- Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trials
- (2012) J.-H. Zhong et al. EJSO
- Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
- (2012) FUJIMASA TADA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
- (2012) Chiun Hsu et al. JOURNAL OF HEPATOLOGY
- Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study
- (2012) Aziz Zaanan et al. JOURNAL OF HEPATOLOGY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- TGFβ signalling in context
- (2012) Joan Massagué NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Feasibility of Gemcitabine plus Oxaliplatin in Advanced Hepatocellular Carcinoma Patients with Child-Pugh B Cirrhosis
- (2012) Marion Dhooge et al. ONCOLOGY
- Immunotherapeutic Approaches to Hepatocellular Carcinoma Treatment
- (2012) Alexander G. Miamen et al. Liver Cancer
- Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma
- (2011) L. Chen et al. EJSO
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis
- (2011) Kang-Jie Chen et al. PLoS One
- Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled Trial
- (2010) Yong Xia et al. ANNALS OF SURGICAL ONCOLOGY
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
- (2010) Ghassan K. Abou-Alfa et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II Study of Oxaliplatin in Patients With Unresectable, Metastatic, or Recurrent Hepatocellular Cancer
- (2009) Y Yen et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
- (2009) Kristy J. Gotink et al. ANGIOGENESIS
- Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma
- (2009) J. O. Lee et al. ANNALS OF ONCOLOGY
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
- (2009) Sandrine Faivre et al. LANCET ONCOLOGY
- A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity
- (2008) J. R. Garlich et al. CANCER RESEARCH
- Recruitment and Activation of Natural Killer Cells In vitro by a Human Dendritic Cell Vaccine
- (2008) K. Gustafsson et al. CANCER RESEARCH
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma
- (2008) Daniel H. Palmer et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started